Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKS-452 Vaccination Study
NCT04681092Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AKS-452 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by University Medical Center Groningen. Primary endpoint: Safety / Tolerability at 35 days. Started Apr 2021; status: completed.
02
Drugs
AKS-452
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04681092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681092.